TYK2 licenses non-canonical inflammasome activation during endotoxemia-Reference-Cited by-同舟云学术

TYK2 licenses non-canonical inflammasome activation during endotoxemia

Published:2020-09-14 Issue:2 Volume:28 Page:748-763
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Poelzl Andrea^ORCID,Lassnig Caroline,Tangermann Simone,Hromadová Dominika^ORCID,Reichart Ursula,Gawish Riem,Mueller Kristina,Moriggl Richard,Linkermann Andreas,Glösmann Martin,Kenner Lukas^ORCID,Mueller Mathias,Strobl Birgit^ORCID

Funder

Austrian Science Fund

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

https://www.nature.com/articles/s41418-020-00621-x.pdf

Reference75 articles.

1. Fuchs S, Kaiser-Labusch P, Bank J, Ammann S, Kolb-Kokocinski A, Edelbusch C, et al. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur J Immunol. 2016;46:2639–49.

2. Kreins AY, Ciancanelli MJ, Okada S, Kong XF, Ramirez-Alejo N, Kilic SS, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212:1641–62.

3. Strobl B, Stoiber D, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed). 2011;16:3214–32.

4. Leitner NR, Witalisz-Siepracka A, Strobl B, Muller M. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. Cytokine. 2017;89:209–18.

5. He X, Chen X, Zhang H, Xie T, Ye XY. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018). Expert Opin Ther Pat. 2019;29:137–49.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of missense mutation-related type 1 diabetes mellitus through integrating genomic databases and bioinformatic approach;Genomics & Informatics;2024-06-26

2. Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection;Journal of Hepatology;2024-06

3. Targeting pyroptosis to treat ischemic stroke: From molecular pathways to treatment strategy;International Immunopharmacology;2024-05

4. Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling;Cellular and Molecular Life Sciences;2024-04-29

5. Regulation of Versican Expression in Macrophages is Mediated by Canonical Type I Interferon Signaling via ISGF3;2024-03-14